Aspivix has just added Tia, the US network of women's health clinics that is revolutionizing care through a more empathetic approach, to its ambassador program. With 26 centers of excellence around the world, once each site has been trained by the end of the week, the program is bringing together experts ranging from private gynecological practices to major teaching hospitals such as the HUG in Switzerland.
In a milestone partnership aimed at improving women's health, ASPIVIX, a leading innovator in gynecological and fertility solutions, and Tia women's health clinics, the modern medical home for women, are redefining the way women experience gynecological care across the United States.
Together, ASPIVIX and Tia will expand access to enhanced IUD procedures and improve experience for women in 9 Tia clinics in Los Angeles, New York, San Francisco and Scottsdale across 3 states. The two healthcare trailblazers share the same mission: to put women first by delivering the care each woman needs and deserves through a people-centered approach. This partnership represents a critical step in that mission, setting new standards in the field of gynecology.
This collaboration will provide comprehensive care and improve patient experiences by offering Carevix™, the advanced, pain-reducing solution for women undergoing IUD insertions, for the first time in the US. This partnership marks ASPIVIX’s further expansion into the U.S. market, following FDA- approval of Carevix™ and positive clinical data presented at ACOG 2024.
Moving away from the use of the traumatic cervical tenaculum, Carevix™ is designed to redefine the standards of care in gynecology, offering a more comfortable and empowering experience for patients and healthcare providers alike for transcervical procedures in gynecology.
"At Tia, we prioritize listening to women and addressing their needs. We know that IUD insertions can be a painful experience, and we’ve heard women’s frustrations about their pain being dismissed or minimized. That’s why we’re excited to partner with ASPIVIX as part of their Ambassador Program to offer Carevix™, a breakthrough device that reduces pain during IUD insertions. By integrating Carevix™ alongside our existing pain management options, we are committed to providing a more comfortable and compassionate experience for our patients." said Devon Klauck, WHNP, Senior Director, Clinical Product at Tia.
"With the CDC urging physicians to better manage pain during IUD procedures, our partnership with Tia represents a victory for women advocating for better care. It’s an important step for ASPIVIX as we continue to align our patient-centric solution," shares Ikram Guerd, General Manager US of ASPIVIX.
Growing coverage in the US
Over 700 patients globally have experienced enhanced care with Carevix™, with over 90% reporting satisfaction for IUD and other transcervical procedures (hysteroscopy, endocervical biopsies...). Women undergoing IUD placement at Tia will now experience a more comfortable and less painful procedure with Carevix™ solution transforming their gynecological care experience. Now, ASPIVIX is excited about expanding the access to Carevix™ to healthcare professionals to improve patient outcomes by redefining together the standard of care in clinical practice.
Carevix™ will be available across 9 clinics (Los Angeles: Studio City, Culver City, Silver Lake, Pasadena, Santa Monica, San Francisco, New York Soho & Williamsburg, Scottsdale) by the end of September 2024. Among its US early adopters are also IU Health Indianapolis and Columbia University in New York, both already using Carevix and offering gentle gynecological procedures (IUD placement, endometrial biopsies…).
(PR - ES)
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines